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Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune disease of unknown etiology that involves multiple
interacting cell types driven by numerous cytokines and autoimmune epitopes. Although the initiating events leading to
SLE pathology are not understood, there is a growing realization that dysregulated cytokine action on immune cells plays
an important role in promoting the inflammatory autoimmune state. We applied phospho-specific flow cytometry to
characterize the extent to which regulation of cytokine signal transduction through the STAT family of transcription factors
is disturbed during the progression of SLE. Using a panel of 10 cytokines thought to have causal roles in the disease, we
measured signaling responses at the single-cell level in five immune cell types from the MRLlpr murine model. This
generated a highly multiplexed view of how cytokine stimuli are processed by intracellular signaling networks in adaptive
and innate immune cells during different stages of SLE pathogenesis. We report that robust changes in cytokine signal
transduction occur during the progression of SLE in multiple immune cell subtypes including increased T cell
responsiveness to IL-10 and ablation of Stat1 responses to IFNa, IFNc, IL-6, and IL-21, Stat3 responses to IL-6, Stat5
responses to IL-15, and Stat6 responses to IL-4. We found increased intracellular expression of Suppressor of Cytokine
Signaling 1 protein correlated with negative regulation of Stat1 responses to inflammatory cytokines. The results provide
evidence of negative feedback regulation opposing inflammatory cytokines that have self-sustaining activities and suggest
a cytokine-driven oscillator circuit may drive the periodic disease activity observed in many SLE patients.
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Introduction
Systemic Lupus Erythematosus (SLE) is a debilitating autoim-
mune disease that can damage multiple organs, induce chronic
renal failure, and lead to severe morbidity and mortality. Current
treatment regimens are limited to non-specific immune suppres-
sion and management of inflammatory symptoms. A characteristic
feature of SLE is the presence of anti-nuclear autoantibodies
(ANA) that form immune complexes with cellular debris and cause
end-organ damage. Although the initiating events leading to SLE
pathology are not understood, it is accepted that cytokine release
from dysregulated immune cells plays a central role in promoting
the autoimmune inflammatory state [1–9].
One of the key unanswered questions is how cytokines modulate
the immune system and subvert its ability to control the
autoimmune state — in particular, how intracellular signaling
networks are ‘‘re-wired’’ by tonic stimulation with extracellular
ligands. We hypothesized that abnormal regulation of cytokine
signal transductionin immune cells is an integral feature of SLE and
that changes incytokine signalingwould paralleldisease progression
and severity. Most cytokines, including those associated with SLE,
signal through the Signal Transduction and Activators of
Transcription (STAT) family of transcription factors. STAT
proteins, upon being phosphorylated at activating residues,
translocate from the plasma membrane to the nucleus where they
drive numerous gene programs critical to immune function[10]. To
quantify STAT signaling responses to cytokines during different
phases of SLE we applied phospho-specific flow cytometry, an
approach uniquely capable of measuring the biochemical activation
of multiple pathways in numerous cell types simultaneously [11,12].
We previously employed this technique to stratify AML patients by
signaling responses [13], map the complexities of the broader
immune signaling network in primary murine cells [14], and
automate the discovery of complex signaling relationships in
primary human T cells using machine learning [15].
Several cytokines accelerate or slow SLE progression in both
mouse and man and there is evidence that interferons play
important roles in both species [2,4,6–8,16–20]. The transcriptional
signature of exposure to type I interferon is detectable in peripheral
blood mononuclear cells (PBMC) of many SLE patients and nearly
all juvenile SLE patients [7,8,21,22]. Murine strains predisposed to
developing lupus that are subsequently rendered homozygous for
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have a longer life-span, a milder disease course, and far less renal
damage than parental strains [17,19] whereas infusions of
exogenous IFNc accelerated disease progression [23]. Similarly,
knocking out the receptor for Type I interferons resulted in later
disease onset, milder symptoms, and slower disease progression
[16,18]. A central role for cytokines in regulating SLE development
is consistent with work in other systems showing that cytokines
orchestrate the initiation, execution, perpetuation, and resolution of
productive immune responses and play critical roles in coordinating
interactions among numerous specialized cell types.
The most direct evidence that interferons have a causal role in
human SLE comes from the high prevalence of SLE-associated
symptoms among patients treated with type I interferons for
conditions like hepatitis and cancer. In one study, 22% of patients
treated with IFNa developed a positive blood test for ANA and
19% developed frank autoimmunity with one patient meeting the
criteria for SLE diagnosis [24]. Interestingly, most patients’
autoimmune symptoms were reversed when IFNa therapy was
withdrawn. These findings show that high levels of IFNa can
induce a form of autoimmunity, that this IFNa autoimmunity can
be induced in a surprisingly large fraction of humans, and that
maintenance of this autoimmunity requires consistently high levels
of IFNa.
This and other research in mice and humans has led to a
reevaluation of models in which autoimmunity is portrayed as rare
and irreversible, held at bay by flawless tolerance. Central
tolerance was shown to be less than perfect by the discovery that
autoreactive T and B cells are a part of the peripheral repertoire of
healthy individuals and that these cells can be activated when
peripheral tolerance is overcome [25]. The frequency with which
IFNa therapy induces autoimmunity is part of a body of evidence
that tolerance can be overcome in a clinical context and raises the
possibility that transient, interferon-induced autoimmunity might
occur more often than previously thought. For example, IFNa
levels can be very high during viral infections, notably higher than
in many SLE patients. Thus, it might be that cytokine-driven
activation of autoreactive lymphocytes is not unique to SLE
patients; however, most individuals do not develop persistent
autoimmunity due to intrinsic processes that inhibit the cytokine-
driven feed-forward loops that maintain the immune state, thereby
allowing the immune system to ‘‘stand down’’ once the pathogen is
cleared.
Although the mechanisms involved in the initiation and early
progression of SLE are thought to be key to understanding the
disease, these processes occur prior to symptomatic manifestations
that drive patients to seek medical assistance. A distinct advantage
of murine models of SLE is that animals can be evaluated prior to
disease onset and the animals also have relatively consistent disease
progression. To test the hypothesis that cytokine signal transduc-
tion is modulated in both pathway- and cell-specific manners that
correlate with SLE disease status, we analyzed samples collected
before disease onset through initiation to the terminally severe
phase using the MRL/lpr murine model of SLE. MRL mice
spontaneously develop autoimmunity with many of the features of
human SLE, including a similar autoantibody profile, autoim-
mune skin and liver disease, and immune-complex glomerulone-
phritis [9,26,27]. A spontaneous mutation, lpr, arose on the MRL
background that greatly accelerated the autoimmune predisposi-
tion of MRL mice. In this report, MRL mice homozygous for the
lpr mutation will be referred to as ‘‘lpr’’ and MRL mice
homozygous wild type at this locus will be referred to simply as
‘‘MRL’’. The onset and progression of SLE in female lpr mice is
extremely consistent [28]. Autoantibody levels are detectable as
early as 6 weeks and a pronounced lymphoadenopathy is observed
at 12 weeks that is largely due to the proliferation of a population
of B220+, TCRb+, CD3+ cells that are mostly CD42 and CD82.
Multiple organs are affected and a steady deterioration of renal
function manifests as heavy proteinuria beginning around 16
weeks of age. Very few lpr mice live past 28 weeks [28]. As such,
this murine model is well suited for evaluation of processes that
underlie each stage of SLE and provides a solid foundation for
comparisons with other murine models of this disease as well as
progression of the human disease.
Of the many signaling systems that are likely important to
immune function, we chose to focus on cytokine stimuli and
signaling pathways thought to have causal or secondary relation-
ships to SLE and that are proximal to initiating events during
immune activation. Inasmuch as others have used the production
of cytokines as a baseline for how autoimmune processes guide
immune cell output, we surmised that phosphorylation of STAT
members in response to a panel of cytokines would provide an
even more vital understanding of how immune cells change how
they process immunomodulatory cues during SLE progression.
We observed a strong correlation between SLE disease status and
the ability of different subsets of primary immune cells to activate
specific STAT signaling pathways in response to a broad range of
cytokine stimuli. Notably, there was potent attenuation of IFNa,
IFNc, and IL-6 signaling across multiple immune cell subsets that
was correlated to periods of increased SLE disease activity,
suggesting that previously unrecognized, negative feedback loops
oppose critical cytokine activities. As existing models of biological
oscillators depend on the presence of negative feedback loops,
often coupled with positive feedback loops [29], our identification
of negative feedback regulation of IFNa signal transduction may
provide a mechanistic explanation of why many SLE patients
oscillate between flare and remission. Our identification of
pathway specific and cell specific dysregulation may have
significant implications for disease monitoring and treatment of
SLE in human patients.
Results
Phospho-profiling of cells from MRL/lpr mice
In preparation for subsequent phospho-profiling experiments,
we stained splenocytes from MRL and lpr mice at varying stages of
disease (5–20 weeks) with antibodies specific to surface markers
considered relevant to disease progression: B220, CD11b, Ly6C,
Ly6G, Gr-1, CD19, IgM, CD21, CD3, TCRb, TCRcd, CD4, and
CD8 [30,31]. From this analysis (Fig. S1 and data not shown), we
determined that use of B220, CD11b, TCRb, CD4, and CD8 for
phospho-specific flow cytometric analysis would capture most
subsets important to disease progression and allow accurate
resolution of populations that changed over time. All antibodies
used for phospho-specific flow cytometric analysis were validated
as previously described [14,32].
To create an understanding of cell-type specific changes as SLE
progresses, we profiled the cytokine response of multiple major
immune cell subsets (Fig. 1A) in two genotypes: lpr as the disease
model and MRL as control. Spleens were harvested from three
mice per genotype at 5, 10, 15, and 20 weeks of age to examine
four stages of SLE progression. Due to a lack of clinical
manifestations of disease, 5 weeks is thought to be pre-disease,
whereas at 10 weeks, lpr mice have detectable ANA and are
thought to be in an early stage of SLE. At 15 weeks, manifestations
of organ damage (e.g., proteinuria) are detectable in many animals
and at 20 weeks the disease is terminally severe. The dissociated
splenocytes from each mouse were stimulated ex vivo with ten
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bias, or immune system regulation. Phosphorylation of Stat1, 3, 5,
and 6 on activating residues was measured in five subsets of
immune cells: CD11b
hi neutrophils and monocytes, B cells, CD4+
T cells, CD8+ T cells, and B220+TCRb+ double positive T cells.
(Fig. 1B) Stat2 and Stat4 phosphorylation was not measured due to
their limited activation by most cytokines in our profile. This
profile was carried out over a 15 week period to map changes in
signaling that occurred as the mice transited from a pre-disease
state, through early and intermediate stages, to the terminally
Figure 1. Experimental design for profiling changes in the murine immune signaling network during SLE progression. (A) MRL and lpr
mice (n=3 each) were profiled at four different ages (5, 10, 15, and 20 weeks). At 20 weeks of age, lpr mice show severe lupus symptoms, while MRL
mice display only mild signs of disease. At each age, the phosphorylation of four Stat proteins (Stat1, Stat3, Stat5, and Stat6) in response to 11
different stimuli (basal, IL-2, IL-4, IL-6, IL-9, IL-10, IL-13, IL-15, IL-21, IFNa, and IFNc) was analyzed in five cell types (B cells, CD11b-hi cells, CD4+ T cells,
CD8+ T cells, and B220+TCRb+ cells). Combination of these variables generated 5,280 response patterns. The histogram pairs under each age display
basal and stimulated states for MRL and lpr mice for one signaling pathway in one particular cell type (e.g., IL-15 activation of Stat5 in CD8+ T cells at
5 weeks of age). The color of the stimulated histogram indicates fold change upon stimulation, black indicating no change, and red indicating .3
fold change. (B) Surface marker analysis used to define five cell types for phospho-flow analysis. Cells were size gated to exclude debris and red blood
cells then gated for CD11b expression to yield CD11b-hi cells. Staining with B220 and TCRb revealed three populations, B cells, T cells, and
B220+TCRb+ cells. The T cells were further sub-gated in CD4+ and CD8+. Numbers represent percentage of cells in each gate. (C) Stimulation with
exogenous cytokines reveals differences in Stat signaling. The median fluorescent intensity (MFI) of phospho-specific staining in CD4+ T cells
averaged across multiple mice is plotted against the age of the mice. Error bars show the standard deviation. The dotted lines display staining in the
basal (unstimulated) state and the solid lines show the staining after stimulation with the indicated cytokine. The stimulation used in each chart is
IFNc, IL-6, IL-10, and IL-15 respectively.
doi:10.1371/journal.pone.0006756.g001
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progressive changes over the time course are shown (Fig. 1C).
The profile resulted in 5,280 nodes where each node is the
phosphorylation status of one Stat protein in response to one
cytokine (or in the unstimulated state) in a particular cell type (e.g.,
Stat3,IL-6, CD4+ T cells).Selected data is summarized inheat map
format (Fig. 2A) with the cytokine-induced fold change in
phosphorylation represented by yellow (increase) or blue (decrease).
In the absence of exogenous stimulation there was no detectable
activation of Stat3 or Stat5 over the disease course, though there
was low but detectable increase in staining for pStat1 and pStat6
that was larger in B cells than in T cells (Fig. 1C, 2B, C, D and Fig.
S2). The cytokine response, however, in four of the five cell types
analyzed changed dramatically over the course of the disease.
Cytokine-induced signaling in cells from MRL and lpr mice was
comparable at 5 weeks of age, prior to disease development, but
differences became apparent at 10 weeks, when lpr mice began to
show symptoms. In several cell types, there was a decrease in
responsiveness to stimulation by certain cytokines (Fig. 2A).
Interestingly, the loss of responsiveness to some cytokines was
initially non-uniform: at 10 weeks of age the Stat1 response to IL-6
was ablated in roughly half of CD4+ T cells while it was high in
the other half (Fig. 2B). CD4+ cells also showed heterogeneity in
their Stat1 response to IFNc as well (data not shown). There was
also differential regulation of pathways activated by the same
cytokine receptor. For example, in T cells from lpr mice there was
a sharp drop in the Stat1 response to IL-21 but a comparatively
modest reduction in the Stat3 response to this cytokine (Fig. 2C).
This pathway specific regulation is even more pronounced when
IL-6 is the stimulus (see below).Although differences between
MRL and lpr mice were first seen at 10 weeks of age, the disparity
in signaling responses became even greater at 15–20 weeks. Both
genotypes showed a downward trend in the Stat1 response to
IFNa as the mice aged, but the lpr mice showed an almost
complete blockade of this pathway in all cell types starting at 10
weeks of age (Fig. 3A). A similar genotype-specific trend was also
apparent for the Stat1 response to IFNc and Stat6 response to IL-
4; these responses remained relatively strong in MRL mice
throughout the time course, but were greatly reduced in lpr mice
from 10 weeks onward (Fig. 3A). Interestingly, while the Stat1
response to IFNc was completely abolished from 10 weeks onward
in all cell types, the Stat6 response to IL-4 remained comparatively
strong in B cells, suggesting Stat1 and Stat6 are regulated by
different mechanisms in this cell type.
Regulation was not limited to decreased signaling responses. T
cells from lpr mice had an enhanced responsiveness to IL-10 at 20
weeks of age compared to the response at 5 weeks (Fig. 3A). T cells
from pre-disease animals or wild type strains showed weak
signaling responses to IL-10 and consistent with this, from five
to fifteen weeks of age B220-TCRb+ T cells of MRL and lpr mice
had responses to IL-10 comparable to those of T cells from
BALB/c mice (data not shown). At 20 weeks, however, the Stat3
response to IL-10 in B220- T cells from lpr mice roughly doubled
compared to the response at 5 weeks and was far greater than that
observed in T cells from MRL or BALB/c mice (Fig. 3A and data
not shown). At every age, the B220+TCRb+ T cells of both
genotypes showed a much larger Stat3 response to IL-10 than
single positive T cells. Elevated responses to IL-10 are of interest
because this cytokine has been implicated in murine and human
SLE in a number of studies [1–5].
The mechanistic changes in signaling derived from this dataset
are organized by receptor in the diagram shown in Fig. 3B. Given
the broad down-regulation of the Stat1 phosphorylation response
to cytokines in lpr mice, we asked whether this lead to functional
consequences in the cognate cells. The most immediate down-
stream implications of impaired activation of Stat1, a transcrip-
tional regulator, should be reduced induction of target gene
transcription by agents that signal through Stat1. Splenic
suspensions from 5 and 20 week old BALB/c, MRL, and lpr
mice were stimulated with IFNc. The levels of mRNA expression
of two representative Stat1 target genes, GBP-1 and IRF-1
[33,34], were determined by a two-color real-time reverse
transcriptase PCR (RT-PCR) assay. Consistent with the Stat1
signaling results, IFNc stimulation strongly induced expression of
both target transcripts in 5-week, but not 20-week, lpr splenocytes
(Fig. 3C). Age did not impair induction of GBP-1 in MRL
splenocytes or induction of either transcript in BALB/c spleno-
cytes. Interestingly, significantly less IRF-1 was induced in MRL
splenocytes at 20 weeks than at 5 weeks, though induction was
stronger at both time points than in lpr mice. Although 20 week
MRL mice had, as expected, greater Stat1 signaling and target
gene induction than age-matched lpr mice, the Stat1 response to
IFNc was weaker in MRL splenocytes at 20 weeks than at 5 weeks
and this reduction in signaling was enough to partially impair
induction of IRF-1 expression. Thus, changes in signaling detected
by phospho-specific flow cytometry correlated with relevant
downstream transcription events in primary immune cells.
Elevated SOCS1 protein levels correlate with differential
inhibition of STAT activation during SLE progression
At the single-cell level, the Stat1 and Stat3 pathways were
differentially regulated as SLE progressed. This was readily
apparent for IL-6, a cytokine whose receptor is responsible for
activating both Stat1 and Stat3 pathways in T cells. Basal
activation of Stat1 and Stat3 in B220-CD4+ and B220-CD8+ T
cells from lpr mice showed little detectable change throughout the
course of the disease (Fig. 4A) and no change was see in T cells
from age-matched MRL mice. In contrast, starting at 10 weeks of
age a large fraction of the B220-CD8+ T cells from lpr mice had a
poor pStat1 response to IL-6 despite the pStat3 response
remaining strong (Fig. 4B column 4, compare row 1 to rows 2–
4). Cell subset specific analysis shows that Stat3 is strongly
phosphorylated after IL-6 stimulation even in B220-CD8+ T cells
that have an undetectable pStat1 response. A similar effect was
observed with B220-CD4+ T cells from 10 week old lpr mice
(Fig. 4B); however, a large proportion of B220-CD4+ T cells from
older lpr mice had poor pStat1 and pStat3 responses to IL-6
(Fig. 4B column 2, compare row 1 to rows 3 and 4). This inhibition
of both pathways in B220-CD4+ T cells may be partly explained
by reduced expression of the IL-6 receptor on the surface of CD4+
T cells from 20 week old lpr mice (Fig. 4C). In contrast, B220-
CD8+ T cells from lpr mice showed no detectable drop in the
expression of the IL-6 receptor consistent with maintenance of the
pStat3 response to IL-6. Differential regulation of two pathways
activated by the same receptor suggested the involvement of
inhibitory cytoplasmic factors. This was further supported by the
finding of the SLE-associated blockade of Stat1 phosphorylation
downstream of other receptors (IL-21, IFNa and IFNc) making it
plausible that Stat1 activation through multiple receptors was
being inhibited by a common cytoplasmic factor. Since IL6
receptor levels were maintained on B220-CD8+ cells and IFNGR1
and IFNGR2 showed no detectable change in expression on any
of the cell types that showed reduced Stat1 responses to IFNc (data
not shown), the observed inhibition of Stat1 signaling must involve
mechanisms other than receptor downregulation.
The suppressor of cytokine signaling-1 (SOCS1) protein is
known to be a potent cytoplasmic inhibitor of Stat activation by
interferons, IL-4 and IL-6 [35–39]; we observed that signaling
Regulation of Signaling in SLE
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SOCS1 knockout mice showed that, at physiological levels,
SOCS1 has no effect on the magnitude or duration of IL6
induced Stat3 activation but does have a significant inhibitory
effect on the magnitude of IL6 induced Stat1 activation [40], so it
is possible that SOCS1 is responsible for the pathway-specific
regulation of IL-6 signaling in early SLE. Therefore, we analyzed
lysates from the splenocytes of BALB/c, MRL, and lpr mice for
SOCS1 protein expression (Fig. 4D and Fig. S3). SOCS1 levels
were low and nearly identical across the three genotypes at 5 weeks
of age, but at 20 weeks there were significant differences between
the genotypes and, as expected, SOCS1 protein expression
inversely correlated with the ability of IFNc to phosphorylate
Stat1 and induce target gene transcription. The highest levels of
SOCS1 were seen in 20 week lpr splenocytes; upon IFNc
stimulation these cells showed barely detectable increases in target
gene expression. The elevated levels of SOCS1 protein were not
simply due to increases in the B220+TCRb+ compartment, as
purified B220-TCRb+CD4+ splenocytes from 20-week lpr mice
showed high levels of SOCS1. In contrast, levels of SOCS3,
another potent inhibitor of IL-6 signaling [39,41], were not
elevated in splenic lysates from 20 week MRL or lpr mice relative
to those in age-matched BALB/c mice (Fig. S3).
Discussion
There is a growing appreciation that inflammatory cytokines
play key roles in the initiation and maintenance of autoimmune
diseases such as SLE [42]. However, existing models do not
account for the fact that cytokines thought to drive autoimmune
disease are found at their highest levels not in autoimmune
patients but in patients mounting protective immune responses to
pathogens [42,43]. Thus, the mere presence of an inflammatory
state is not sufficient to drive autoimmunity, but aberrant control
of immune cell responses to inflammatory cytokines may disrupt
the delicate balance between immunity and self-reactivity. In this
study, we observed dysregulation of cytokine signal transduction
that correlated with disease activity in a mouse model of SLE. In
healthy individuals, negative feedback regulation may be required
to oppose the inflammatory state and restore homeostasis, but in
SLE, regulation may be deficient and a chronic state of aberrant
immune activation may result.
Figure 2. SLE progression is accompanied by reduced potentiation of multiple signaling nodes. (A) Heat map representation of Stat
protein phosphorylation on activating residues induced by cytokine stimulation. Data is shown for CD4+ T cells, CD8+ T cells, B cells, and B220+TCRb+
cells. Each square represents one signaling node which corresponds to the change in phosphorylation of one STAT protein in response to a cytokine
in the specified cell type from one mouse. Each cytokine has four rows of data corresponding to stimulation of cells from mice at each age (increasing
downward: 5, 10, 15, and 20 weeks). Three MRL and lpr mice were evaluated at each age; for a given row the first three columns of each Stat
correspond to data from three MRL mice and the next three columns to that from three lpr mice. Note disease-associated changes in IFNa, IFNc, IL-6
and IL-21 signaling. (B) Histograms show the phosphorylation of Stat1 in response to IL-6 (first two columns) or IFNc (second two columns) in CD4+ T
cells. The gray-shaded histograms are the pStat1 staining of the unstimulated cells and the color-shaded histograms are the staining of the samples
stimulated with IL-6 or IFNc. Note the bimodal histogram shape present in 10 week old lpr mice. (C) The entire dataset is multidimensional. Contour
plots of Stat1 and Stat3 phosphorylation in CD4+ T cells in the unstimulated state, and in response to IL-21 and IFNa. (D) Stat5 and Stat6
phosphorylation in CD8+ T cells in the unstimulated state, and in response to IL-15 and IL-4.
doi:10.1371/journal.pone.0006756.g002
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pathways activated by the same receptor that were differentially
regulated at the single-cell level. After the onset of SLE, the Stat1
response to IL-6 and IL-21 was poor in the same T cells that
exhibited strong activation of Stat3 (Fig. 2C and Fig. 4B). This
suggests that the observed differential regulation occurs in the
cytoplasm, since reduced receptor expression would be expected to
inhibit both pathways. We observed an increase in SOCS1 protein
levels during SLE progression, suggesting that SOCS1 is a
cytoplasmic mediator that plays a role in this pathway-specific
regulation (Fig. 4C–E). Although over-expression studies have
shown that SOCS family members are highly promiscuous in their
inhibitory activities against JAK proteins, there is growing
evidence that at physiological levels SOCS are more specific to
particular STAT protein isoforms[40]. SOCS1 was first identified
for its potent ability to inhibit JAK2 activity[35] and the
mechanism for its JAK2 preference over JAK1 was later defined
[44]. Knockout studies have shown JAK2 to critical for the Stat1
response to IL-6, but dispensable for the Stat3 response to this
cytokine[45]. The selective inhibition of the Stat1 response to IL-6
Figure 3. SLE progression is accompanied by highly specific blockade of cytokine-induced STAT signaling and target gene
induction. (A) Detailed analysis of 24 signaling nodes. Data points are averaged from three mice; error bars represent standard deviation. By 10
weeks of age there were large decreases in the cytokine/STAT responses of multiple splenic cell types from lpr mice and these changes were
pathway- and cell-type specific. Note that inhibition of some pathways (e.g., IL-4/pStat6) was cell-type specific. (B) Diagrams outlining the cytokine/
STAT pathways modulated. (C) Real-time RT-PCR was used to quantify GBP-1 and IRF-1 transcript abundance in BALB/c, MRL, and lpr splenocytes
taken from mice at 5 and 20 weeks of age in the absence and presence of IFNc. Measurements were normalized to b-actin internal controls prior to
calculation of fold induction.
doi:10.1371/journal.pone.0006756.g003
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protein. (A) Basal phosphorylation of Stat1 and Stat3 in B220-, CD4 and CD8 single positive T cells from lpr mice at 5, 10, 15, and 20 weeks of age.
The same subsets from MRL mice have basal signaling that does not change with age and resembles that of 5-week-old lpr mice (not shown). (B)
Phosphorylation of Stat1 and Stat3 in CD4 and CD8 single positive T cells after stimulation with IL-6. Nearly all single positive T cells from MRL mice
show strong phosphorylation of Stat1 and Stat3 after stimulation with IL-6 and that did not change with age. In lpr mice, starting at 10 weeks, a large
proportion of CD8+ T cells lost the pStat1 response to IL-6 but maintained pStat3 response to this cytokine at every age. Cells are in the upper left
quadrant because, at the single-cell level, there is strong IL-6-induced phospho-activation of Stat3, but little or no detectable phospho-activation of
Stat1. CD4+ T cells from 10-week-old lpr mice had no detectable pStat1 response to IL-6 and at later time points an increasing proportion of CD4+ T
cells lost the pStat3 response as well. To the right of these two-dimensional plots is a set of color bars that summarize the severity of SLE in the lpr
mice through time. (C) Flow cytometric analysis of IL-6 receptor expression on CD4 and CD8 single positive T cells at 20 weeks of age. (D) Western
blot analysis of SOCS1 protein levels at 5 and 20 weeks in splenocytes from BALB/c, MRL, and lpr mice and from the CD4+ fraction. The relative
abundance of SOCS1 at 20 weeks normalized to bActin is shown numerically under the blots. (E) Model of pathway-specific IL-6 signaling blockade.
Differential blockade of pStat1 response to IL-6 may be due to selective inhibition of JAK2 activity by SOCS1. JAK2 activity is required for Stat1
phosphorylation but dispensable for Stat3 phosphorylation.
doi:10.1371/journal.pone.0006756.g004
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of SOCS1 that specifically target JAK2 activity while having
relatively little influence on JAK1 (Fig. 4E). This suggests a model
in which SOCS1 levels rise during SLE and inhibit the Stat1
responses to IL-6, IL-21, and interferons with comparatively little
influence on Stat3 signaling including the Stat3 responses to IL-6
and IL-10. Consequently, one would expect that genes whose
promoters are driven by Stat1 homodimers (or Stat1-Stat3
heterodimers) would be inhibited in their normal regulatory
patterns starting from early SLE onset. This provides direct
mechanistic consequences for immune activities driven by these
transcription factors.
The MRL/lpr model is only one of several models of SLE, all of
which are understood to be imperfect representations of human
disease [46]. However, lpr mice do exhibit many of the features of
human SLE, including a similar autoantibody profile, autoimmune
skin and liver disease, and immune-complex glomerulonephritis. As
with other murine models of SLE, interventions that oppose
interferon action reduce the severity of the disease in these mice. In
this study, we observed strong negative regulation of signaling
responses to cytokines thought to have causal roles in murine and
human SLE. Importantly, we found that many of the signaling
responses that were ablated during the progression of SLE in the lpr
mice were also reduced in cells from SLE patients with non-zero
SLE Disease Activity Index (SLEDAI) scores (in preparation).
Given the presumed role of interferon in SLE, it was surprising
that the phosphorylation of Stat1 and the transcriptional response
to interferons was greatly reduced as SLE progressed in lpr mice.
Although this seems counterintuitive, both Type I and Type II
interferons have been shown to potently induce negative feedback
regulation of Stat1, in part by inducing SOCS1 [37–39,47,48].
SOCS1 levels were elevated in the lpr mice (Fig. 4D) and in SLE
patients (in preparation). Indeed, a blockade of Stat1 signaling
may be the inevitable result of interferon activity and this blockade
has been shown to be induced during protective Th1 responses,
potentially allowing lymphocytes to survive the deleterious effects
of prolonged interferon exposure [49]. Since infection is a leading
cause of death for SLE patients [50], it is possible that a prolonged
state of reduced responsiveness to IFNa may further compromise a
patient’s ability to fight infection. The blockade of Stat1 signal
transduction and elevated SOCS1 protein levels we observed in
the progression of murine SLE suggest that between 5 and 10
weeks-of-age, strong interferon signaling induces negative feed-
back regulation of Stat1. Consistent with this, Stat1 basal
activation was detectably elevated at 10 weeks-of-age even though
exogenous interferon stimulation was not able to induce the high
level of Stat1 activation observed in age-matched MRL mice.
From 10 weeks onward in lpr mice, Stat1 activation in response to
exogenous stimulation was greatly reduced compared to MRL
mice, but IFNc was still able to induce some expression of target
genes GBP-1 and IRF-1, though induction was markedly weaker
than when Stat1 signal transduction was strong (Fig. 3C).
In the context of SLE, this negative feedback regulation of
cytokine signal transduction fails to permanently silence autoim-
munity and instead may play a role in destabilizing the immune
system. Biological oscillators have been found to require negative
feedback [29]. Different relative contributions of negative and
positive feedback result in a bi-stable system, a system that is
essentially ‘‘on’’ or ‘‘off’’ but has no stable intermediate state [51].
An effective immune system is designed to be bi-stable: fully
activated in response to pathogen challenge and quickly turning
completely off when the pathogen is cleared. It is possible that
disturbances in the coupling of negative and positive feedback
elements, such as interferon signaling, may destabilize and shift the
immune system from a bi-stable system to one that oscillates
between flare and remission as observed in many SLE patients.
Consistent with this hypothesis, we have found negative regulation
of the same cytokine signaling pathways reported here is present in
a large fraction of SLE patients, and robust changes in cytokine
signaling were found to precede flare (manuscript in preparation).
Oscillations between flare and remission are not observed in all
human patients, or in murine models, therefore a longitudinal
study of patients transiting between flare and remission will be
required to better understand the role of feedback regulation. Our
identification of negative feedback regulation of interferon
signaling in this study provides evidence that an interferon-driven
oscillator could play a role in cycling between flare and remission.
In summary, we find that changes in STAT signaling parallel
SLE progression in a murine model of SLE. Critically, basal
phosphorylation alone did not robustly discriminate disease states
from each other or from non-diseased individuals, but interroga-
tion of cells with environmental cues (cytokines) revealed altered
signaling nodes that did correlate with disease progression. This is
consistent with our observations of human leukemia [13] where
basal signaling was of limited value in predicting clinical outcome,
but signaling responses were indicative of cell character and were of
significant prognostic value. Thus, in conjunction with conven-
tional indicators, quantifying the disturbed nature of cytokine
action in SLE could lead to approaches that objectively
characterize disease status at the level of single-cell signaling states
and may point to therapies that safely modulate the disease by
modifying cell and cytokine responses.
Materials and Methods
Antibodies and reagents
Antibodies against murine CD3 (clone 145-2C11), TCRcd (GL-
3), TCRb (H57-597), CD4 (GK1.5), CD8 (53–6.7), B220 (RA3-
6B2), CD19 (ID3), CD21 (7G6), IgM (11/41), Ly6C (AL-21),
Ly6G (1A8), Gr-1 (RB6-8C5), and CD11b (M1/70) were kindly
provided by BD Biosciences (La Jolla, CA). Surface antibodies
were conjugated to Alexa 488, FITC, PE, Cy5.5.PerCP, Cy7PE,
Pacific Blue, APC, Alexa 700, or Cy7APC. Antibodies against the
phospho-proteins Stat1 Y701 (4A), Stat3 Y705 (4), Stat5 Y694
(47), Stat6 Y641 (J71-773.58.11) conjugated to Alexa 488 or Alexa
647 were also provided by BD Biosciences. SOCS-1 antibody was
from Zymed (clone 38–5200). Recombinant murine (rm) IFNc,
IL-2, IL-4, IL-6, IL-9, IL-10, IL-13, and IL-21 were from BD.
rmIFNa was from R&D Systems (Minneapolis, MN). rmIL-15 was
from Peprotech (Rocky Hill, NJ). All cytokines were used at a final
concentration of 50 ng/mL, except for murine IL-10 which was
used at 100 ng/mL and murine IFNa which was used at 100 U/
mL. Dose-response experiments verified that these concentrations
were at least 5-fold higher than the minimum concentration
needed to achieve maximal phospho-activation of the downstream
Stat. Taqman probes specific to murine b-actin, Gbp-1, and IRF-1
were obtained from Applied Biosystems (Foster City, CA). The
one-step rtPCR enzyme mix used was Superscript with Platinum
Taq (Invitrogen, Carlsbad, CA).
Murine SLE sample preparation
MRL +/+ (MRL) and MRL lpr/lpr (lpr) mice were obtained
from Jackson Laboratories (Bar Harbor, ME) and were housed at
the Stanford Animal Facility from 5–20 weeks of age. All mice
were handled in accordance with APLAC and Stanford University
animal care guidelines. BALB/c mice were obtained from Jackson
or from the in-house colony at Stanford and were age-matched to
MRL and lpr mice. At the desired age, spleens were harvested and
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5610
6 cells/mL in RPMI-1640 containing 10% FBS and PSQ
(RPMI-10).
Murine surface marker analysis
Splenocytes were pelleted and resuspended at 10
7 cells/mL in
staining medium (PBS containing 0.5% BSA and 0.02% sodium
azide). Appropriate surface marker antibodies were added at
optimal dilutions and samples were incubated for 30 minutes on
ice. Cells were then washed once with at least 20 volumes of
staining media and analyzed by flow cytometry on a FACSCalibur
instrument fitted with 488 and 633 lasers (BD Biosciences, San
Jose, CA). At least 100,000 cells were analyzed for each sample.
Cytokine stimulation and phospho-flow
Murine splenocytes were cultured at 37uC for 2 hours in RPMI-
10 to allow for recovery from the splenic dissociation. Cytokines
were added to the culture media and the cells incubated for 15
minutes at 37uC, fixed for 10 minutes at room temperature with
formaldehyde directly added to the medium (1.5% final
concentration), and then pelleted. The cells were resuspended in
MeOH previously chilled to 4uC and then stored at 280uC until
phospho-flow analysis. Samples were removed from 280uC
storage, washed two times with staining media, and resuspended
at 10
7 cells/mL in staining media. Staining was with a cocktail of
antibodies, including CD11b Ax405, TCRb PE, B220 Cy5.5-
PerCP, CD8 Cy7PE, CD4 Cy7APC and the combination of
pStat3 Ax488 and pStat1 Ax647 or the combination of pStat5
Ax488 and pStat6 Ax647. Samples were stained for 30 minutes,
washed once with staining media, and analyzed on an LSRII flow
cytometer equipped with 405, 488, and 633 nm lasers. Digital
data was acquired with BD Diva software with .75,000 size-gated
cells collected per data point. Data was analyzed in FlowJo
software. Median fluorescence intensity (MFI) was used to
calculate the fold change between stimulated and unstimulated
cells: fold change=MFIstim/MFIunstim. A log2 fold change was
derived so that samples showing no stimulation had a value of
zero, those that showed increases in phospho-protein levels were
positive, and those that showed decreases were negative. Flow
cytometric data from this study can be found online at: http://
proteomics.stanford.edu/nolan/.
Real-time RT-PCR and western blotting
RNA preparations and lysates for western analysis were
obtained from a fraction of each spleen immediately after
harvesting to determine basal expression levels. The remaining
cells were cultured as a single cell suspension at 37uC for 2 hours
in RPMI-10. The suspensions were then cultured for an additional
2.5 hours in the presence or absence of IFNc. The cells were
pelleted and then lysed in Trizol for 15 minutes at room
temperature. Samples were stored at 280uC in Trizol prior to
RNA isolation. After extraction from Trizol and isopropanol
precipitation, the RNA was further purified using RNeasy columns
(Qiagen, Valencia, CA) and was resuspended in water. Transcript
quantitation was normalized to b-actin internal controls. Fold
induction was calculated as the ratio of transcript abundance after
culture in the presence of IFNc to abundance after culture in the
absence of IFNc. All western blots were performed with whole cell
lysates, resolved by SDS-PAGE, transferred to PVDF (Immobilon-
P, Millipore, Billerica, MA), and blotted for SOCS-1. Blots were
quantified using ImageJ software and were analyzed in parallel
using LumiAnalyst3.0 software. As a positive control, 293T cells
were transfected with a SOCS1 expression construct in a
pcDNA3.1 backbone and lysates were prepared after 24 or
36 hours.
Supporting Information
Figure S1 Changes in splenic immune compartments during
SLE. Splenocytes from MRL and lpr mice of the specified ages
were stained with cocktails of surface antibodies (TCRb, B220,
CD4, CD8, CD19, CD21, IgM) and analyzed by flow cytometry.
(A) Total splenocytes analyzed for B220 and TCRb expression
were gated into B cells (B220+TCRb-), T cells (TCRb+B220-),
and B220+TCRb+ cells. Note increases in B220+TCRb popula-
tion in lpr mice at 10–20 weeks. Other notable changes are
indicated by highlights or arrows. (B) B cells (CD19+B220+) were
analyzed for IgM and CD21 expression. Immature (CD21- IgM-
hi), mature (CD21-int IgM-int), marginal zone (CD21-hi IgM-hi),
and CD21-IgM- populations were gated. (C) T cells (B220-
TCRb+) were analyzed for CD4 and CD8 expression. (D)
B220+TCRb cells were also analyzed for CD4 and CD8
expression. Note the presence of a large double-negative
population, characteristic of the lpr model.
Found at: doi:10.1371/journal.pone.0006756.s001 (9.38 MB TIF)
Figure S2 SLE progression induces small differences in basal
phospho-Stat1 and phospho-Stat6 staining. Splenic suspensions
were not stimulated prior to fixation, permeabilization, and
analysis. Shown is the phospho-specific staining of B220-
TCRb+CD4+ T cells and B220+TCRb- B cells. Each point
represents the median fluorescent intensity averaged across three
mice and normalized to the median fluorescent intensity averaged
across three 5 week old MRL mice. The error bars display the
normalized standard deviation.
Found at: doi:10.1371/journal.pone.0006756.s002 (0.09 MB TIF)
Figure S3 SOCS1 antibody validation and blotting SOCS1 and
SOCS3. (A) The human fibroblast line 293T was mock transfected
or transfected with a SOCS1 expression construct employing the
pcDNA3.1 backbone. Lysates were prepared 24 and 40 hours
after transfection, resolved by SDS-PAGE, transferred to PVDF
membrane, and blotted with different anti-SOCS1 primary
antibodies and then with appropriate HRP-conjugated secondary
antibodies. The membrane shown here was blotted with Zymed
38–5200 as the primary. This antibody was used for all SOCS1
expression analysis of SLE material; it correctly recognized a 30
kDa band that was much more intense (.10 fold) in lanes
containing lysates from cells transfected with the SOCS1
expression construct than those from control 293T lysates. In
contrast, blots using Santa Cruz SC-7001 as primary did not show
differential staining in the absence and presence of the SOCS1
expression construct so this antibody was not used in our analysis
of SLE material. (B) Comparison of 20 week old BALB/c, MRL,
and lpr splenic lysates showed differential staining with Zymed 38–
5200 primary. This is an experimental replicate that shows the
same trend displayed in Figure 4D. Quantitation of the SOCS1
bands normalized to ,lower case beta.Actin is shown in the red
bar graph below the blot. (C) MRL and lpr mice were found to
have comparable levels of SOCS3 when analyzed using Santa
Cruz SC-7009 as primary. Quantitation of the SOCS3 bands
normalized to ,lower case beta.Actin is shown in the blue bar
graph below the blot.
Found at: doi:10.1371/journal.pone.0006756.s003 (0.79 MB TIF)
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